Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Aged
Anti-Bacterial Agents
/ therapeutic use
Azabicyclo Compounds
/ therapeutic use
Boronic Acids
/ therapeutic use
Carbapenem-Resistant Enterobacteriaceae
/ drug effects
Carbapenems
Ceftazidime
/ therapeutic use
Cohort Studies
Drug Combinations
Drug Resistance, Multiple, Bacterial
/ drug effects
Enterobacteriaceae Infections
/ drug therapy
Female
Humans
Male
Meropenem
/ therapeutic use
Middle Aged
Retrospective Studies
Treatment Outcome
Urinary Tract Infections
/ drug therapy
beta-Lactamase Inhibitors
/ pharmacology
Gram-negative resistance
carbapenem-resistant Enterobacteriaceae
ceftazidime-avibactam
meropenem-vaborbactam
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
21 04 2020
21 04 2020
Historique:
received:
19
11
2019
accepted:
13
02
2020
pubmed:
26
2
2020
medline:
7
4
2021
entrez:
26
2
2020
Statut:
epublish
Résumé
The comparative efficacy of ceftazidime-avibactam and meropenem-vaborbactam for treatment of carbapenem-resistant
Identifiants
pubmed: 32094128
pii: AAC.02313-19
doi: 10.1128/AAC.02313-19
pmc: PMC7179589
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azabicyclo Compounds
0
Boronic Acids
0
Carbapenems
0
Drug Combinations
0
avibactam, ceftazidime drug combination
0
beta-Lactamase Inhibitors
0
vaborbactam
1C75676F8V
avibactam
7352665165
Ceftazidime
9M416Z9QNR
Meropenem
FV9J3JU8B1
Types de publication
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 American Society for Microbiology.
Références
Antimicrob Agents Chemother. 2014 Jul;58(7):4035-41
pubmed: 24798270
Clin Infect Dis. 2019 Jan 18;68(3):519-524
pubmed: 30020449
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28848018
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29507064
Crit Care. 2007;11(2):R31
pubmed: 17331245
Curr Infect Dis Rep. 2020 Jan 13;22(1):1
pubmed: 31933158
Infect Control Hosp Epidemiol. 2016 Mar;37(3):281-8
pubmed: 26686227
Open Forum Infect Dis. 2015 May 05;2(2):ofv050
pubmed: 26125030
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28167547
Antimicrob Agents Chemother. 2016 Dec 27;61(1):
pubmed: 27799202
J Clin Microbiol. 2017 Sep;55(9):2573-2582
pubmed: 28724555
J Antimicrob Chemother. 2018 Mar 1;73(3):648-657
pubmed: 29228202
Diagn Microbiol Infect Dis. 2013 Feb;75(2):115-20
pubmed: 23290507
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29133570
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618
pubmed: 27624958
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 29038260
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28396547
Clin Microbiol Infect. 2016 May;22(5):444-50
pubmed: 26850826
Clin Infect Dis. 2018 Jan 6;66(2):163-171
pubmed: 29020404
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28031201
Antimicrob Agents Chemother. 2018 Dec 21;63(1):
pubmed: 30578403
Infect Dis Ther. 2018 Dec;7(4):439-455
pubmed: 30270406
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28559250
Clin Infect Dis. 2019 Nov 18;:
pubmed: 31738396